{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:05:21Z","timestamp":1790629521016,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.07.008","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:26:22Z","timestamp":1790627182000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["My\u00e9lome multiple en 2026\u00a0: strat\u00e9gies th\u00e9rapeutiques en situation de rechute"],"prefix":"10.1016","author":[{"given":"Pierre-Edouard","family":"Debureaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titouan","family":"Cazaubiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chalopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bulcan.2026.07.008_bib0160","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.bulcan.2026.07.008_bib0165","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and paradigms in multiple myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.bulcan.2026.07.008_bib0170","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.07.008_bib0175","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.07.008_bib0180","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S1470-2045(25)00280-3","article-title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","volume":"26","author":"Manier","year":"2025","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.07.008_bib0185","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.clml.2025.05.015","article-title":"Retreatment with anti-CD38-based combinations in multiple myeloma in real-life: results from the emmy cohort study","volume":"25","author":"Talbot","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10245","key":"10.1016\/j.bulcan.2026.07.008_bib0190","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3\u00a0study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"10292","key":"10.1016\/j.bulcan.2026.07.008_bib0195","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3\u00a0trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.008_bib0200","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3\u00a0trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10214","key":"10.1016\/j.bulcan.2026.07.008_bib0205","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3\u00a0study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.008_bib0210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/joim.12882","article-title":"Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension","volume":"286","author":"Bringhen","year":"2019","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.008_bib0215","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3\u00a0trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2026.07.008_bib0220","unstructured":"Inc MG. Carfilzomib-pomalidomide-dexamethasone in relapsed\/refractory\u2026 by Pierre-Edouard Debureaux [Internet]. [cited 2026\u00a0March 16]. Available from: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4160825\/pierre-edouard.debureaux.carfilzomib-pomalidomide-dexamethasone.in.relapsed.html?f=listing%3D3\u00a0%2Abrowseby%3D8\u00a0%2Asortby%3D1\u00a0%2Amedia%3D1."},{"issue":"10262","key":"10.1016\/j.bulcan.2026.07.008_bib0225","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3\u00a0trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.008_bib0230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.46989\/001c.143641","article-title":"Improving advanced-line multiple myeloma care: insights and real-world challenges from the EMMY study","volume":"7","author":"Cazaubiel","year":"2025","journal-title":"Clin Hematol Int"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2026.07.008_bib0235","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2\u00a0MajesTEC-1\u00a0trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.07.008_bib0240","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3\u00a0study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.008_bib0245","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjh.19505","article-title":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry","volume":"205","author":"Ferment","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.008_bib0250","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3324\/haematol.2024.286118","article-title":"Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program","volume":"110","author":"Perrot","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.008_bib0255","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","article-title":"Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM","volume":"14","author":"Malard","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.008_bib0260","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"23","key":"10.1016\/j.bulcan.2026.07.008_bib0265","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel versus standard regimens in triple-class\u2013exposed relapsed and refractory multiple myeloma: updated KarMMa-3\u00a0analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2026.07.008_bib0270","doi-asserted-by":"crossref","first-page":"e70260","DOI":"10.1002\/hem3.70260","article-title":"Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: practical guidance from the European Myeloma Network","volume":"9","author":"van de Donk","year":"2025","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.bulcan.2026.07.008_bib0275","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clml.2025.04.005","article-title":"Real-world evidence supports venetoclax as an additional option for patients with t(11;14) myeloma","volume":"25","author":"Higu\u00e9","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.bulcan.2026.07.008_bib0280","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.008_bib0285","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2026.07.008_bib0290","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood-2025-256","article-title":"Phase 2\u00a0registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: updated results from iMMagine\u20131","volume":"146","author":"Patel","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2026.07.008_bib0295","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2026.07.008_bib0300","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2026.07.008_bib0305","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.008_bib0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual targeting of extramedullary myeloma with talquetamab and teclistamab","volume":"394","author":"Kumar","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:26:26Z","timestamp":1790627186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S0007455126003942"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"My\u00e9lome multiple en 2026\u00a0: strat\u00e9gies th\u00e9rapeutiques en situation de rechute","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}